<DOC>
	<DOCNO>NCT00990613</DOCNO>
	<brief_summary>To estimate absorption , safety , tolerability dimebon transdermal solution relative dimebon immediate release oral formulation .</brief_summary>
	<brief_title>A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Caucasian , male female , 50 85 year inclusive . Subjects must adequate space available side upper middle back free excessive hair , break irritated skin , tattoo , scar , mole , acne , sunburn . Evidence history major medical psychiatric illness unstable medical condition within six month Screening may increase risk associate study participation . Subjects central nervous system disease include Alzheimer 's disease , Parkinson 's disease , Huntington disease , form dementia . Subjects history stroke , know cerebrovascular disease subject history structural brain disease . Any history epilepsy , seizure disorder ( i.e. , include febrile seizure ) convulsion . Subjects skin disorder might prevent application dimebon solution include , limited , know sensitivity adhesive .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>percutaneous transcutaneous dimebon transdermal pharmacokinetics</keyword>
</DOC>